MetrioPharm AG is a clinical-stage biopharmaceutical development company focused on therapies for acute and chronic inflammatory diseases. MetrioPharm is developing a novel class of self-regulating immunomodulators targeting activated macrophages and inflamed tissues.
Products, services, technology
Compounds from the MP1000 platform are orally available small molecules with a potent anti-inflammatory activity targeting oxidative stress in immune cells.
Cooperation possibilities
Licensing, strategic partnerships, investments
- https://metriopharm.com
- +41 44 515 21 97
- info@metriopharm.com
- Lia Petridou
